Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Study of Repeat Intranodal Injections of Ad-ISF35
A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD154 (Ad-ISF35) in Patients With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)
Status: Enrolling
Updated:  11/30/2015
University of California San Diego, Moores Cancer Center
1049
mi
from 98109
La Jolla, CA
Study of Repeat Intranodal Injections of Ad-ISF35
A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD154 (Ad-ISF35) in Patients With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)
Status: Enrolling
Updated: 11/30/2015
University of California San Diego, Moores Cancer Center
1049
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Status: Enrolling
Updated:  11/30/2015
University of California San Diego, Moores Cancer Center
1049
mi
from 98109
La Jolla, CA
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Status: Enrolling
Updated: 11/30/2015
University of California San Diego, Moores Cancer Center
1049
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  12/1/2015
Tufts Medical Center
2485
mi
from 98109
Boston, MA
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 12/1/2015
Tufts Medical Center
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  12/1/2015
Cedars-Sinai Medical Center
962
mi
from 98109
Los Angeles, CA
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 12/1/2015
Cedars-Sinai Medical Center
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  12/1/2015
City of Hope National Medical Center
959
mi
from 98109
Duarte, CA
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 12/1/2015
City of Hope National Medical Center
959
mi
from 98109
Duarte, CA
Click here to add this to my saved trials
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  12/1/2015
Mayo Clinic Arizona
1113
mi
from 98109
Scottsdale, AZ
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 12/1/2015
Mayo Clinic Arizona
1113
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  12/1/2015
Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 12/1/2015
Moffitt Cancer Center
2522
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  12/1/2015
Northwestern University
1733
mi
from 98109
Chicago, IL
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 12/1/2015
Northwestern University
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  12/1/2015
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 12/1/2015
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated:  12/1/2015
Georg-August Universität
5025
mi
from 98109
Göttingen,
Zevalin-beam for Aggressive Lymphoma
SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma
Status: Enrolling
Updated: 12/1/2015
Georg-August Universität
5025
mi
from 98109
Göttingen,
Click here to add this to my saved trials
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
Phase I Trial of Carfilzomib (PR-171) in Combination With Vorinostat (SAHA) in Patients With Relapsed/Refractory B-Cell Lymphomas
Status: Enrolling
Updated:  12/2/2015
University of Rochester
2161
mi
from 98109
Rochester, NY
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
Phase I Trial of Carfilzomib (PR-171) in Combination With Vorinostat (SAHA) in Patients With Relapsed/Refractory B-Cell Lymphomas
Status: Enrolling
Updated: 12/2/2015
University of Rochester
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
Phase I Trial of Carfilzomib (PR-171) in Combination With Vorinostat (SAHA) in Patients With Relapsed/Refractory B-Cell Lymphomas
Status: Enrolling
Updated:  12/2/2015
Virginia Commonwealth University Massey Cancer Center
2352
mi
from 98109
Richmond, VA
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
Phase I Trial of Carfilzomib (PR-171) in Combination With Vorinostat (SAHA) in Patients With Relapsed/Refractory B-Cell Lymphomas
Status: Enrolling
Updated: 12/2/2015
Virginia Commonwealth University Massey Cancer Center
2352
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at UMC North/University Medical Center
1219
mi
from 98109
Tucson, AZ
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at UMC North/University Medical Center
1219
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at UMC North
1219
mi
from 98109
Tucson, AZ
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at UMC North
1219
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
Phase I Study of GX15-070 (NSC # 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  12/3/2015
City of Hope Medical Center
959
mi
from 98109
Duarte, CA
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
Phase I Study of GX15-070 (NSC # 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 12/3/2015
City of Hope Medical Center
959
mi
from 98109
Duarte, CA
Click here to add this to my saved trials
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Silicon Phthalocyanine Pc4 for Photodynamic Therapy of Cutaneous T-cell Lymphoma: Single and Repeated Photoexposures
Status: Enrolling
Updated:  12/3/2015
University Hospitals Seidman Cancer Center
2024
mi
from 98109
Cleveland, OH
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Silicon Phthalocyanine Pc4 for Photodynamic Therapy of Cutaneous T-cell Lymphoma: Single and Repeated Photoexposures
Status: Enrolling
Updated: 12/3/2015
University Hospitals Seidman Cancer Center
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated:  12/3/2015
Karmanos Cancer Institute
1932
mi
from 98109
Detroit, MI
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated: 12/3/2015
Karmanos Cancer Institute
1932
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated:  12/3/2015
Memorial Sloan Kettering Cancer Center
2402
mi
from 98109
New York, NY
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated: 12/3/2015
Memorial Sloan Kettering Cancer Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated:  12/3/2015
Abramson Cancer Center, Hospital of the Univ. of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated: 12/3/2015
Abramson Cancer Center, Hospital of the Univ. of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated:  12/3/2015
Pharmacy/PCAM/West Pavillion
2367
mi
from 98109
Philadelphia, PA
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated: 12/3/2015
Pharmacy/PCAM/West Pavillion
2367
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Enrolling
Updated:  12/3/2015
Cancer and Leukemia Group B
1733
mi
from 98109
Chicago, IL
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Enrolling
Updated: 12/3/2015
Cancer and Leukemia Group B
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Imexon for Relapsed Follicular and Aggressive Lymphomas
A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults
Status: Enrolling
Updated:  12/4/2015
Arizona Cancer Center, University of Arizona
1220
mi
from 98109
Tucson, AZ
Imexon for Relapsed Follicular and Aggressive Lymphomas
A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults
Status: Enrolling
Updated: 12/4/2015
Arizona Cancer Center, University of Arizona
1220
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
Imexon for Relapsed Follicular and Aggressive Lymphomas
A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults
Status: Enrolling
Updated:  12/4/2015
Univ of Rochester Medical Center
2161
mi
from 98109
Rochester, NY
Imexon for Relapsed Follicular and Aggressive Lymphomas
A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults
Status: Enrolling
Updated: 12/4/2015
Univ of Rochester Medical Center
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status: Enrolling
Updated:  12/4/2015
Northeast Georgia Cancer Care
2211
mi
from 98109
Athens, GA
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status: Enrolling
Updated: 12/4/2015
Northeast Georgia Cancer Care
2211
mi
from 98109
Athens, GA
Click here to add this to my saved trials
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status: Enrolling
Updated:  12/4/2015
Charleston Area Medical Center
2130
mi
from 98109
Charleston, WV
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status: Enrolling
Updated: 12/4/2015
Charleston Area Medical Center
2130
mi
from 98109
Charleston, WV
Click here to add this to my saved trials
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status: Enrolling
Updated:  12/4/2015
21st Century Oncology
1102
mi
from 98109
Sun City, AZ
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status: Enrolling
Updated: 12/4/2015
21st Century Oncology
1102
mi
from 98109
Sun City, AZ
Click here to add this to my saved trials
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status: Enrolling
Updated:  12/4/2015
Illinois Cancer Specialists
1721
mi
from 98109
Niles, IL
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status: Enrolling
Updated: 12/4/2015
Illinois Cancer Specialists
1721
mi
from 98109
Niles, IL
Click here to add this to my saved trials
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status: Enrolling
Updated:  12/4/2015
Park Nicollet Institute
1386
mi
from 98109
St. Louis Park, MN
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy
Status: Enrolling
Updated: 12/4/2015
Park Nicollet Institute
1386
mi
from 98109
St. Louis Park, MN
Click here to add this to my saved trials
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Phase 1, Dose Escalation Study To Assess the Safety, Pharmacokinetics and Activity of 2-Hour Continuous Intravenous Dosing of ON 013105 Administered Weekly in Patients With Relapsed/Refractory Lymphoma and Acute Lymphoid Leukemia
Status: Enrolling
Updated:  12/7/2015
H. Lee Moffitt Cancer Center & Research Institute
2522
mi
from 98109
Tampa, FL
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Phase 1, Dose Escalation Study To Assess the Safety, Pharmacokinetics and Activity of 2-Hour Continuous Intravenous Dosing of ON 013105 Administered Weekly in Patients With Relapsed/Refractory Lymphoma and Acute Lymphoid Leukemia
Status: Enrolling
Updated: 12/7/2015
H. Lee Moffitt Cancer Center & Research Institute
2522
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Receptor
Status: Enrolling
Updated:  12/7/2015
H. Lee Moffitt Cancer Center & Research Institute
2522
mi
from 98109
Tampa, FL
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Receptor
Status: Enrolling
Updated: 12/7/2015
H. Lee Moffitt Cancer Center & Research Institute
2522
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Pinnacle Oncology
1113
mi
from 98109
Scottsdale, AZ
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Pinnacle Oncology
1113
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Tower Cancer Research Foundation
959
mi
from 98109
Beverly Hills, CA
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Tower Cancer Research Foundation
959
mi
from 98109
Beverly Hills, CA
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
University of Maryland Greenebaum Cancer Center
2327
mi
from 98109
Baltimore, MD
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
University of Maryland Greenebaum Cancer Center
2327
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Hackensack University Medical Center
2394
mi
from 98109
Hackensack, NJ
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Hackensack University Medical Center
2394
mi
from 98109
Hackensack, NJ
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Sarah Cannon Research Institute
1971
mi
from 98109
Nashville, TN
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Sarah Cannon Research Institute
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
South Texas Accelerated Research Therapeutics
1780
mi
from 98109
San Antonio, TX
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
South Texas Accelerated Research Therapeutics
1780
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Northwestern University
1733
mi
from 98109
Chicago, IL
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Northwestern University
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy
Status: Enrolling
Updated:  12/9/2015
Memorial Sloan Kettering Cancer Center
2402
mi
from 98109
New York, NY
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy
Status: Enrolling
Updated: 12/9/2015
Memorial Sloan Kettering Cancer Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy
Status: Enrolling
Updated:  12/9/2015
Weill Cornell Medical Center
2402
mi
from 98109
New York, NY
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy
Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy
Status: Enrolling
Updated: 12/9/2015
Weill Cornell Medical Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
A Phase II Trial of Total Body Irradiation-Based Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/10/2015
Northside Hospital
2174
mi
from 98109
Atlanta, GA
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
A Phase II Trial of Total Body Irradiation-Based Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/10/2015
Northside Hospital
2174
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies
Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia
Status: Enrolling
Updated:  12/10/2015
Massey Cancer Center
2352
mi
from 98109
Richmond, VA
High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies
Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia
Status: Enrolling
Updated: 12/10/2015
Massey Cancer Center
2352
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
A Study of the HSP90 Inhibitor AUY922
A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma
Status: Enrolling
Updated:  12/14/2015
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
A Study of the HSP90 Inhibitor AUY922
A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma
Status: Enrolling
Updated: 12/14/2015
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab
Status: Enrolling
Updated:  12/14/2015
University of Pennsylvania; Abramson Cancer Center; Lymphoma Program
2371
mi
from 98109
Philadelphia, PA
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab
Status: Enrolling
Updated: 12/14/2015
University of Pennsylvania; Abramson Cancer Center; Lymphoma Program
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  12/15/2015
Marin Cancer Care, Inc.
669
mi
from 98109
Greenbrae, CA
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 12/15/2015
Marin Cancer Care, Inc.
669
mi
from 98109
Greenbrae, CA
Click here to add this to my saved trials
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  12/15/2015
UC San Diego Moores Cancer Center
1055
mi
from 98109
La Jolla, CA
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 12/15/2015
UC San Diego Moores Cancer Center
1055
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  12/15/2015
Pacific Shores Medical Group
981
mi
from 98109
Long Beach, CA
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 12/15/2015
Pacific Shores Medical Group
981
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  12/15/2015
Ventura County Hematology Oncology Specialists
941
mi
from 98109
Oxnard, CA
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 12/15/2015
Ventura County Hematology Oncology Specialists
941
mi
from 98109
Oxnard, CA
Click here to add this to my saved trials
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  12/15/2015
Cancer Center of Santa Barbara
921
mi
from 98109
Santa Barbara, CA
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 12/15/2015
Cancer Center of Santa Barbara
921
mi
from 98109
Santa Barbara, CA
Click here to add this to my saved trials
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  12/15/2015
Georgetown University Medical Center
2322
mi
from 98109
Washington,
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 12/15/2015
Georgetown University Medical Center
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated:  12/15/2015
Collaborative Research Group
2701
mi
from 98109
Boynton Beach, FL
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling
Updated: 12/15/2015
Collaborative Research Group
2701
mi
from 98109
Boynton Beach, FL
Click here to add this to my saved trials